Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study

Publication
Article
BioPharm InternationalBioPharm International-11-01-2001
Volume 14
Issue 11

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Experience shows that murine MAbs used in cell therapy manufacturing can be produced with safety concerns in mind. In such cases, adequate characterization ensures that they retain functional integrity.

Recent Videos
David Fairen-Jimenez
Industry Outlook 2025: The Rising Prominence of AI in Pharma
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.